Authors

Alireza Ghoreifi, MD, Duke University Department of Urology, and member of the Society of Urologic Oncology (SUO) Fellow.

Latest:

Dr Ghoreifi on the Feasibility for Consolidative Surgery After Enfortumab Vedotin/Pembrolizumab in Advanced Urothelial Cancer

Alireza Ghoreifi, MD, discusses the feasibility of consolidative surgery for advanced urothelial cancer receiving pembrolizumab/enfortumab vedotin.

Kala Visvanathan, MD, MBBS, MHS

Latest:

Dr. Visvanathan on the Rationale for Evaluating Lipophilic Statins in Epithelial Ovarian Cancer

Kala Visvanathan, MD, MBBS, MHS, discusses the rationale for evaluating lipophilic statins in epithelial ovarian cancer.

Alex McDaniel

Latest:

Seeing Medicine Through the Eye of an Artist

For many people who go into research, there’s a moment somewhere along the way that is immediately addictive and makes you want to experience that over and over again.

Francesco Di Meo, PhD

Latest:

Dr Di Meo on the Rationale for Developing LILRB4–Directed CAR T-Cell Therapy in Multiple Myeloma

Francesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.

Jérôme Fayette, MD, PhD

Latest:

Dr Fayette on the Efficacy of Petosemtamab Plus Pembrolizumab in Metastatic HNSCC

Jerôme Fayette, MD, PhD, discusses findings from a trial of frontline petosemtamab plus pembrolizumab in patients with recurrent/metastatic HNSCC.

Lori A. Leslie, MD, Hackensack University Medical Center

Latest:

Dr Leslie on the Management of CAR T-Cell Therapy Toxicities in LBCL

Lori A. Leslie, MD, discusses the evolution in managing toxicities associated with CAR T-cell therapy in patients with LBCL.

Idoroenyi Amanam, MD

Latest:

Dr Amanam on Currently Available JAK Inhibitors for Myelofibrosis

Idoroenyi Amanam, MD, discusses the JAK inhibitors he most commonly reaches for in his clinical practice when treating patients with myelofibrosis.

Jeremy M. Pantin, MD

Latest:

Dr Pantin on the Evolving Treatment Paradigm in PNH

Jeremy M. Pantin, MD, discusses the evolution of the PNH treatment paradigm and agents that are available or being investigated in this disease.

Adam Bagg, MD, University of Pennsylvania

Latest:

Future Treatment Landscape of AML

Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.

Rosa M. Polan, MD

Latest:

Dr Polan on Perioperative Outcomes With Supracervical or Total Hysterectomy Plus Colorectal Resection

Rosa M. Polan, MD, discusses key data from a comparison of perioperative outcomes with supracervical and total hysterectomy performed with concurrent colorectal resection in women.

Saurabh Dahiya, MBBS

Latest:

Dr. Dahiya on Long-Term, Real-World Follow-Up of Axi-Cel in LBCL

Saurabh Dahiya, MBBS, discusses real-world data observed from a long-term follow-up of axicabtagene ciloleucel in large B-cell lymphoma.

Zarnie Lwin, MBBS, FRACP

Latest:

Dr. Lwin on Patient Selection for LEAP-005 Study in CRC, Biliary Tract Cancer, and More

Zarnie Lwin, MBBS, FRACP, discusses patient selection, including those with colorectal cancer, for the phase 2 LEAP-005 study.

Brenna Williams, FNP-C, APRN-NPI

Latest:

Managing Immunotoxicities With CAR T-Cell Therapy for B-ALL

Experts discuss their combined experience with cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and other immunotoxicities post chimeric antigen receptor (CAR) T-cell therapy, whether Moffitt Cancer Center implements a standardized protocol to address and resolve cell therapy–associated immunotoxicities, how interventions are modified across grades of severity, and the use of prophylactic strategies to mitigate treatment-related adverse events as well as the roles of the multidisciplinary team in patient monitoring during the initial 30 days and the longer-term postinfusion period.

Steven Chan, MD

Latest:

Importance of Real-World Data in Supporting Treatment Options

Panelists discuss the insights from real-world data on the effectiveness of cabozantinib, regorafenib, and ramucirumab in second-line treatment for unresectable hepatocellular carcinoma, highlighting the differences between strict eligibility criteria and more flexible modified criteria in patient selection.

Northwestern University Feinberg School of Medicine

Latest:

Northwestern Medicine Performs the Highest Number of Lung Transplants in the United States

The Canning Thoracic Institute became the highest-volume lung transplant center in the US and achieved the shortest wait time for a lung transplant.

Albert Einstein Cancer Center

Latest:

Prominent Scientist Julio Aguirre-Ghiso, Ph.D., To Lead New Cancer Dormancy and Tumor Microenvironment Institute at Albert Einstein Cancer Center

Leading cancer biologist Julio Aguirre-Ghiso, PhD, has been named founding director of the Cancer Dormancy and Tumor Microenvironment Institute, director of the Gruss-Lipper Biophotonics Center, and co-leader of the AECC Tumor Microenvironment and Metastasis Program.

Jonathan L. Kaufman, MD

Latest:

Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MM

The relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.

Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

Latest:

Next Steps in Mantle Cell Lymphoma